Memantine Hydrochloride
Product Images NDC 0615-8264

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 0615-8264). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Memantine HCl Er Caps 28mg 8264 Lupin 1)

Chemical structure of memantine hydrochloride, showing the molecular framework with an amino group (NH2) and hydrochloride (HCl) indicated. The molecule includes a bicyclo ring system with methyl (CH3) substituents.*

FDA Label Image

Figure 2 (Memantine HCl Er Caps 28mg 8264 Lupin 2)

A line graph showing the mean change from baseline in SIB (Severe Impairment Battery) score over 24 weeks of treatment. Two groups are compared: Memantine HCl Extended-Release 28 mg/AChEI and Placebo/AChEI. The graph includes error bars representing SEM and shows clinical improvement versus clinical decline trends.*

FDA Label Image

Figure 3 (Memantine HCl Er Caps 28mg 8264 Lupin 3)

A cumulative percentage curve graph showing patient response measured by SIB (Severe Impairment Battery) change from baseline. The graph compares Memantine HCl Extended-Release 28 mg/AChEI (filled circles) to Placebo/AChEI (open circles), illustrating their respective cumulative percentage of patients across different SIB change values.*

FDA Label Image

Figure 4 (Memantine HCl Er Caps 28mg 8264 Lupin 4)

A line graph showing the mean CBIC-Plus scores over 24 weeks of treatment comparing Memantine HCl Extended-Release 28 mg/AChEI and Placebo/AChEI groups. The x-axis represents weeks of treatment from 0 to 24, and the y-axis shows the mean scores with indications for clinical improvement and clinical decline. Memantine HCl group shows a stable or improved trend, while the placebo group shows a decline over time.*

FDA Label Image

Figure 5 (Memantine HCl Er Caps 28mg 8264 Lupin 5)

Bar chart comparing percentages of patients by CIBIC Plus Rating between Memantine HCl Extended-Release 28 mg/AChEI and Placebo/AChEI groups. Categories on x-axis: Marked Improvement, Moderate Improvement, Minimal Improvement, No Change, Minimal Worsening, Moderate Worsening, Marked Worsening; y-axis shows percentage of patients from 0 to 50%.*

FDA Label Image

Principal Display Panel (Memantine HCl ER Caps 28mg blistercard label)

Medication label for Memantine HCl ER Capsules 28 mg, listed as once-daily dose, with quantity 30 capsules. The label includes lot and expiration placeholders and references packaging by Vangard Labs in Glasgow, KY. It instructs storage at controlled room temperature and dispensing in a tight container. Multiple barcode stickers of the same product details appear for institutional use, with markings for lot and expiration dates placeholder. Manufactured by Lupin as noted on label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.